Researchers Submit Patent Application, "Trispecific Antibodies Specific For Her2 And A Blood Brain Barrier Receptor And Methods Of Use", for Approval (USPTO 20230212312).

The trispecific antibody of claim 1, wherein the third antigen binding site comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 192 or SEQ ID NO: 205 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 193. The trispecific antibody of claim 1, wherein the third antigen binding site comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 166 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 167 or a humanized version thereof. The trispecific antibody of claim 1, wherein the third antigen binding site comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 178 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 179 or a humanized version thereof. [Extracted from the article]

Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)